EP0396169A2 - Composition pharmaceutique pour utilisation topique ophtalmique ayant une tolérance locale modifiée - Google Patents

Composition pharmaceutique pour utilisation topique ophtalmique ayant une tolérance locale modifiée Download PDF

Info

Publication number
EP0396169A2
EP0396169A2 EP90200951A EP90200951A EP0396169A2 EP 0396169 A2 EP0396169 A2 EP 0396169A2 EP 90200951 A EP90200951 A EP 90200951A EP 90200951 A EP90200951 A EP 90200951A EP 0396169 A2 EP0396169 A2 EP 0396169A2
Authority
EP
European Patent Office
Prior art keywords
bendazac
composition
composition according
active ingredient
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP90200951A
Other languages
German (de)
English (en)
Other versions
EP0396169A3 (fr
Inventor
Bruno Silvestrini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Publication of EP0396169A2 publication Critical patent/EP0396169A2/fr
Publication of EP0396169A3 publication Critical patent/EP0396169A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention relates to a pharmaceutical composition for topical ophthalmic use having improved local tolerability, which comprises from 0.1 to 3 moles of free lysine for each mole of an active ingredient selected from bendazac, 5-OH bendazac and the salts thereof with pharmaceutically acceptable organic and inorganic bases.
  • US patent No. 4.451.477 and European patent application A-0191520 disclose some pharmaceutical dosage forms for topical ophthalmic use containing bendazac or 5-OH bendazac or a salt thereof with a physiologically acceptable organic or inorganic base, respectively. Lysine salt is cited in both said documents.
  • bendazac lysinate also known as bendaline
  • free lysine is used to mean lysine not salified by bendazac or 5-OH bendazac.
  • bendazac or 5-OH bendazac are used as starting material in the preparation of the pharmaceutical composition of this invention, from 1.1 to 4 moles of lysine are added to each mole of said active ingredients because one mole is needed for salifying the active ingredient itself.
  • the composition of this invention contains from 0.2 to 2.5 moles of free lysine. More preferably it will contain from 0.5 to 2 moles of free lysine.
  • Suitable salts of bendazac and 5-OH bendazac are sodium, potassium, methylamine, isopropylamine, hexylamine, diethyl amine, ethanolamine, 2-hydroxymethyl-2-amino-1,3-­propanediol, arginine and lysine salts.
  • Typical examples of preferred salts are lysine and arginine salts.
  • the dosage forms of this invention are preferably liquid, such as solutions, or semiliquid, such as creams.
  • Aqueous solutions are a typical example of a preferred dosage form.
  • the dosage forms of this invention may contain preservatives, stabilizers, humectants, emulsifiers, buffers and the like.
  • composition of this invention may also contain other ophthalmologic active ingredients and are prepared and sterilized according to known techniques.
  • a collyrium containing 0.5% by weight of bendazac lysinate is currently used in the treatment of cataract. In some patients having hypersensitive eyes, this collyrium causes local irritation consisting in burning sensation and reddening. In 20 of these patients a comparison test between the commercially available bendazac lysinate collyrium (A) and a collyrium modified by mere addition of lysine (B) was carried out.
  • the two collyriums had the following compositions: Collyrium A Bendazac lysinate 0.500 g Boric acid 1.000 g Borax 0.135 g Hydroxypropylmethylcellulose 0.500 g Potassium chloride 0.310 g Sterilized purified water up to 100 ml Collyrium B Bendazac lysinate 0.500 g Lysine 0.188 g Boric acid 0.380 g Potassium chloride 0.810 g Hydroxypropylmethylcellulose 0.500 g Sterilized purified water up to 100 ml
  • the test was carried out in double blindness conditions.
  • the subjects hypersensitive to bendaline were divided into two homogeneous groups. Three drops of one of the two collyriums were instilled in one eye of each subject while 3 drops of a physiological saline solution were instilled in the other eye. After some hours the test was repeated by instilling the other collyrium, while still applying physiological saline solution to the other eye. The results show that collyrium B is almost indistinguishable from physiological saline solution while collyrium A causes reddening and burning sensation.
  • Lysine was tested at lower concentrations also, obtaining a less effective but still appreciable protective action. At higher concentrations lysine is well tolerated and excellent local tolerability was observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19900200951 1989-04-26 1990-04-18 Composition pharmaceutique pour utilisation topique ophtalmique ayant une tolérance locale modifiée Ceased EP0396169A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8920275A IT1229674B (it) 1989-04-26 1989-04-26 Composizione farmaceutica per uso topico oftalmico contenente bendazac o 5-0h bendazac
IT2027589 1989-04-26

Publications (2)

Publication Number Publication Date
EP0396169A2 true EP0396169A2 (fr) 1990-11-07
EP0396169A3 EP0396169A3 (fr) 1991-05-22

Family

ID=11165354

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900200951 Ceased EP0396169A3 (fr) 1989-04-26 1990-04-18 Composition pharmaceutique pour utilisation topique ophtalmique ayant une tolérance locale modifiée

Country Status (5)

Country Link
US (1) US5093348A (fr)
EP (1) EP0396169A3 (fr)
JP (1) JP2846405B2 (fr)
CA (1) CA2015427A1 (fr)
IT (1) IT1229674B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565734B (zh) * 2013-09-27 2015-01-21 武汉武药科技有限公司 一种苄达赖氨酸滴眼液及其制备方法
CN116850182A (zh) * 2021-04-30 2023-10-10 远大医药（中国）有限公司 用于治疗近视的方法和药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3202561A1 (de) * 1980-07-29 1983-08-04 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A., Roma Lysinsalze der ((1-benzyl-1h-indazol-3-yl)-oxy)-essigsaeure, verfahren zu deren herstellung und diese enthaltende arzneimittel
EP0191520A1 (fr) * 1985-02-12 1986-08-20 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Acide(phénylméthyl-1 hydroxy-5 1H-indazolyl-3)oxyacétique et ses sels utiles comme médicaments et compositions pharmaceutiques les contenant

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1189052B (it) * 1981-11-27 1988-01-28 Acraf Trattamento della cataratta

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3202561A1 (de) * 1980-07-29 1983-08-04 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A., Roma Lysinsalze der ((1-benzyl-1h-indazol-3-yl)-oxy)-essigsaeure, verfahren zu deren herstellung und diese enthaltende arzneimittel
EP0191520A1 (fr) * 1985-02-12 1986-08-20 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. Acide(phénylméthyl-1 hydroxy-5 1H-indazolyl-3)oxyacétique et ses sels utiles comme médicaments et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
US5093348A (en) 1992-03-03
JPH02295925A (ja) 1990-12-06
EP0396169A3 (fr) 1991-05-22
CA2015427A1 (fr) 1990-10-26
IT8920275A0 (it) 1989-04-26
JP2846405B2 (ja) 1999-01-13
IT1229674B (it) 1991-09-06

Similar Documents

Publication Publication Date Title
EP0326915B1 (fr) Composition thérapeutique à usage local pour traiter les maladies inflammatoires
DE69019774T2 (de) Isochinolin-Derivate zur Behandlung des Glaukoms oder der okulären Hypertonie.
EP1553953B1 (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
EP0235544B1 (fr) Composition oculaire antihypertensive pour l'utilisation topique
JPS6038323A (ja) 眼科用消炎剤
KR910005885B1 (ko) 염화리소짐 및 글리치르히진산 디칼륨 함유 수용액제제
JPH1160505A (ja) 防腐組成物
GB2110532A (en) Bendazac compositions for treatment of cataract
JPS61143318A (ja) 新規な製剤およびその調整方法
CA1139669A (fr) Composes pour traiter le glaucome
US4197301A (en) Topical ophthalmic use of Prazosin
WO1999038497A2 (fr) Composition ophtalmique
EP0695545B1 (fr) Utilisation de dérivés du diphényléthane pour la fabrication d'un médicament pour le traitement du glaucome
JPH06316519A (ja) 薬剤で誘導される瞳孔拡大を抑制し又は拡大された瞳孔を 縮小するための、一定のスルファモイル置換フェネチルア ミン誘導体の使用、及びそれに用いる局部的投与組成物
US5093348A (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
CA1333362C (fr) Traitement de l'inflammation oculaire
US5519030A (en) Method for prophylaxis and treatment of myopia
JPH0469342A (ja) 水性医薬製剤
CA2065889C (fr) Augmentation du debit choroidien
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
EP0205606B1 (fr) Compositions pharmaceutiques et leur utilisation comme agents mydriatiques
JPH0330571B2 (fr)
US4322425A (en) Compositions for treating glaucoma
US4694022A (en) Fatty acid salts of betaxolol useful in the treatment of glaucoma
EP0375299A1 (fr) Mélanges d'inhibiteurs ACE et CA pour le traitement du glaucome

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17P Request for examination filed

Effective date: 19910719

17Q First examination report despatched

Effective date: 19920514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19921108